Fusion Comprising A Cell Penetrating Peptide, A Multi Epitope And A TLR Peptide Agonist For Treatment Of Cancer
US 12,220,387 In forceTerm ends Sep 21, 2037 · Low confidence
20-year base term ends Sep 21, 2037
Sep 21, 2017
Sep 21, 2037
Feb 11, 2025
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Sep 21, 2017, when the earliest non-provisional application in its chain was filed (this one was filed Apr 12, 2022); a parent in its chain could not be resolved (the next row) | Sep 21, 2037 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | +170 days, USPTO patent term adjustment record | Mar 10, 2038 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 11,338,027) | capped to Sep 21, 2037 | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 0 of 3 maintenance fees paid | In force | High confidence |
| Further caveats on record | The record names parents not resolved: 17104786, 16331398 | Low confidence overall | Low confidence |
| Computed term end | The steps above, in order | Sep 21, 2037 | Low confidence |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Not on this page: the patent's family, its recorded assignments and its citation count. USPTO's assignment records, linked above, list every recorded assignment.
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.